Artificial intelligence news.
Straight from the original announcements.

i-Lumen Reports Dry AMD Signals in i-SIGHT Feasibility Study

November 10, 2026, 15:17By the AI News Bites Editorial TeamSource: PR Newswire
i-Lumen Reports Dry AMD Signals in i-SIGHT Feasibility Study
Image: PR Newswire

i-Lumen Scientific reported findings from a randomized, sham-controlled feasibility study of its investigational AMD System, identifying potential improvements in visual function, retinal electrophysiology and structural biomarkers in people with dry age-related macular degeneration. The company said the results support further evaluation in larger controlled clinical trials.

Key points
  • The i-SIGHT study enrolled 30 participants across 10 U.S. retina centers.
  • The active study eye showed a mean change of +9.62 EDTRS letters at Month 3.
  • More than 50% of treated participants achieved a ≥10-letter improvement at one or more follow-up visits.
  • No unanticipated device-related adverse events were reported.
  • The larger i-SIGHT2 Study is enrolling in the US and the UK.

Study tested noninvasive retinal stimulation

The multicenter i-SIGHT trial evaluated the i-Lumen AMD System in patients with vision loss caused by intermediate to advanced nonexudative, or dry, age-related macular degeneration. The study enrolled 30 participants across 10 U.S. retina centers and assessed safety, visual function, retinal electrophysiology and retinal structural biomarkers.

Participants completed an initial 5-day treatment regimen, followed by one-day treatment visits at Months 1 and 2. They were followed through the Month 12 time point. The investigational device delivers low-level microcurrent stimulation through the eyelid, with the intended effect of influencing retinal bioelectrical signaling.

According to i-Lumen, proposed mechanisms include restoration of the retinal pigment epithelium's transepithelial electrical potential, which may support retinal homeostasis and photoreceptor function.

Results included visual and imaging signals

The mean change from baseline for the active study eye was +9.62 EDTRS letters at Month 3. In exploratory analyses, active study eyes showed an +8.54 ETDRS-letter advantage relative to untreated fellow eyes at Month 3, and a +3.9 ETDRS-letter advantage compared with sham.

More than 50% of treated participants achieved a ≥10-letter improvement in best-corrected visual acuity at one or more follow-up visits between Months 2 and 12. Improvements in photoreceptor response time, measured through multifocal electroretinography, were associated with improvements in visual acuity.

Exploratory optical coherence tomography analyses showed improvement in ellipsoid zone integrity during the treatment period. The maximum observed improvement was 47.6% by week 2, with a sustained improvement of 39% by Month 3.

No unanticipated device-related adverse events were reported, and overall adverse event rates were comparable between the active and sham groups.

Larger i-SIGHT2 trial is enrolling

The findings were presented by Sophie J. Bakri, MD, MBA, Professor and Chair of Ophthalmology at Mayo Clinic, following the 2026 Clinical Trials at the Summit Retina meeting.

“While the study was not designed to establish definitive efficacy, the signals observed in visual acuity, retinal electrophysiology, and imaging biomarkers support further evaluation in larger controlled clinical trials,” Bakri said.

i-Lumen has initiated the larger pivotal i-SIGHT2 Study and is currently enrolling participants in the US and the UK. The company described the study as an important step toward potential treatment options for intermediate to advanced dry AMD, where it says significant unmet need remains.

The i-Lumen AMD System remains under clinical investigation. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for commercial use. The company also cautioned that feasibility-study results may not predict outcomes in larger clinical trials.

i-Lumen Scientifici-Lumen AMD SystemSophie J. BakriMayo Clinichealthcareresearch findings

Related news

Ascletis reports preclinical results for oral and long-acting obesity drugs
ResearchNovember 16, 2026, 10:10

Ascletis reports preclinical results for oral and long-acting obesity drugs

Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said…

SAS and Posit Partner on Governed AI for Life Sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit Partner on Governed AI for Life Sciences

SAS and Posit PBC have formed a partnership to give life sciences organizations more flexibility in using SAS and open-source technologies, initially for clinical…

Mayo Clinic names Matthew R. Callstrom as next president and CEO
BusinessNovember 13, 2026, 21:09

Mayo Clinic names Matthew R. Callstrom as next president and CEO

Mayo Clinic has elected Matthew R. Callstrom, M.D., Ph.D., as its next president and CEO, succeeding Gianrico Farrugia, M.D. Farrugia will remain in the role through…